Fingolimod Improves Anxiety-like Behavior and Modulates Sphingosine-1-Phosphate Receptors Gene Expression in a...

Area of Science:

• Neuroscience
• Endocrinology
• Pharmacology

Background:

• Type 2 diabetes mellitus (T2DM) is a global health crisis linked to cognitive impairments.
• Sphingosine-1-phosphate receptors (S1PRs) regulate cell survival and inflammation, but their role in the T2DM brain is unknown.

Purpose of the Study:

• To investigate the effects of fingolimod, an S1PR modulator, on the brain in a mouse model of T2DM.
• To examine gene expression related to S1PRs, glucose metabolism, insulin signaling, and inflammation.

Main Methods:

• Diabetic mice were treated with fingolimod (FTY720).
• Behavioral tests assessed anxiety and memory.
• Gene expression analysis was performed on brain tissue for S1PRs, sphingosine kinases, glucose transporters, insulin signaling proteins, SIRT1, and cytokines.

Main Results:

• T2DM mice exhibited memory deficits, anxiety, and altered gene expression (decreased S1pr1, Sirt1, Igf1; increased Sphk2, S1pr3, Il6, Tnf).
• Fingolimod treatment normalized S1pr1, Sirt1, and Igf1 expression, and upregulated glucose transporter (Slc2a4/GLUT-4) and insulin-degrading enzyme (Ide).
• Fingolimod reduced pro-inflammatory cytokine expression (Il6, Tnf) and improved anxiety-like behavior.

Conclusions:

• S1PR modulation plays a significant role in T2DM.
• Fingolimod positively impacts brain gene expression related to glucose metabolism and insulin signaling.
• Fingolimod demonstrates therapeutic potential for improving cognitive and behavioral deficits in T2DM.